# Ifenprodil as a ReMyelinating repurpOsed Drug in Multiple Sclerosis

> **NCT06330077** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 60 (estimated)

## Conditions studied

- Multiple Sclerosis
- Remitting Relapsing Multiple Sclerosis

## Interventions

- **DRUG:** Ifenprodil
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06330077
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-03
- **Primary completion:** 2027-03
- **Final completion:** 2027-06
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06330077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06330077, "Ifenprodil as a ReMyelinating repurpOsed Drug in Multiple Sclerosis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06330077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*